“Questcor Pharmaceuticals (QCOR) has been upgraded by TheStreet Ratings from hold to buy. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.”
,” TheStreet’s analyst wrote.
Shares of Questcor Pharmaceuticals traded down 0.87% during mid-day trading on Thursday, hitting $30.6299. Questcor Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $58.91. The stock’s 50-day moving average is currently $26.76. The company has a market cap of $1.797 billion and a P/E ratio of 11.94.
Several other analysts have also recently commented on the stock. Analysts at Mizuho upgraded shares of Questcor Pharmaceuticals from a neutral rating to a buy rating in a research note to investors on Thursday. They now have a $41.00 price target on the stock, up previously from $28.00. Separately, analysts at Lazard Capital Markets reiterated a buy rating on shares of Questcor Pharmaceuticals in a research note to investors on Monday, December 31st. They now have a $74.00 price target on the stock.
Six research analysts have rated the stock with a buy rating, and three have given a hold rating to the company. Questcor Pharmaceuticals has a consensus rating of overweight and an average target price of $44.71.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.